AR and neoplasm: Tumor resistance to androgen receptor (AR) targeted chemotherapy in metastatic castration resistant prostate cancer (MCPRC) due to intratumoral androgen mutation, expansion, steroid increase, AR splice variant expression, and androgen independent tumor cell development (211).